UNITAID Report On Delinking R&D Costs From Medicines Prices
Delinkage of research and development costs from medicines prices could "vastly expand" access to medicines by drastically dropping costs of the knowledge component of health products, innovative medicines R&D facility UNITAID says in a new report.





